## PHG Needs Assessment Calculator

#### Eritrea

Glucose-6-phosphate dehydrogenase deficiency

Welcome to the PHG Health Needs Assessment Calculator for Glucose-6-phosphate dehydrogenase deficiency. The contents of this file are listed below.

Full name of the sheet	Short name
Country demographic, maternal health and socioeconomic indicators	Demography
Country health service data	HealthServices
G6PD Epidemiology 1.1: Country epidemiology	G6PD-E1.1
G6PD Epidemiology 1.2: International comparison	G6PD-E1.2
G6PD Epidemiology 2.1: Data on affected pregnancies: Research studies	G6PD-E2.1
G6PD Epidemiology 2.2: Data on affected pregnancies: Surveillance	G6PD-E2.2
G6PD Epidemiology 2.3: Data on affected pregnancies: Other sources	G6PD-E2.3
G6PD Epidemiology 2.4: Summary of affected pregnancies	G6PD-E2.4
G6PD Epidemiology 2.5: Sub-population variation in affected pregnancies	G6PD-E2.5
G6PD Epidemiology 3.1: Mortality data: Research studies	G6PD-E3.1
G6PD Epidemiology 3.2: Mortality data: Vital registration data	G6PD-E3.2
G6PD Epidemiology 3.3: Mortality data: Other sources	G6PD-E3.3
G6PD Epidemiology 3.4: Summary mortality estimates	G6PD-E3.4
G6PD Epidemiology 3.5: Sub-population variation in mortality	G6PD-E3.5
G6PD Epidemiology 4.1: Population prevalence: Research studies	G6PD-E4.1
G6PD Epidemiology 4.2: Population prevalence: Other sources	G6PD-E4.2
G6PD Epidemiology 4.3: Summary of population prevalence	G6PD-E4.3
G6PD Epidemiology 4.4: Sub-population prevalence variation	G6PD-E4.4
G6PD Interventions 1: Newborn screening and management	G6PD-Interv1
G6PD Needs Assessment Calculator 1: Quantitative baseline	G6PD-NA1
G6PD Needs Assessment Calculator 3: Quantitative assessment of interventions	G6PD-NA3

(There is no sheet G6PD-NA2.)

# Eritrea Shared Data Demographic, maternal health and socio-economic indicators

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Demography information from that Calculator into here. The information should be the same.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Number of persons by age-group and sex		Estimates		Your estimates			Chosen estimates			
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total	
0-4 years	549179	530110	1079289			0			0	
5-9 years	525938	509139	1035077			0			0	
10-14 years	492090	481523	973613			0			0	
15-19 years	434856	431337	866193			0			0	
20-24 years	371818	375696	747514			0			0	
25-29 years	326377	337526	663903			0			0	
30-34 years	282042	295519	577561			0			0	
35-39 years	230506	244378	474884			0			0	
40-44 years	181554	200161	381715			0			0	
45-49 years	140031	161534	301565			0			0	
50-54 years	116240	135378	251618			0			0	
55-59 years	93205	109982	203187			0			0	
60-64 years	72071	85246	157317			0			0	
65+ years	149523	183031	332554			0			0	
Total	3965430	4080560	8045990	0	0	0	0	0	0	
Female population aged 15-44 years		1884617			-			-		
Data year		2010 re	eported in							
Source, Year			UN 2011							

Ethnicity. Please enter data for the main ethnic groups if you are working with a population that is different from that of the country.

Ethnic group	Number	% population

Fertility and mortality	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Crude birth rate: live births (LB) / year / 1000 population	35.51	Unicef, 2013				
Still birth rate (SB): Still births (SB) / year / 1000 total births	21.20	WHO, 2009				
Total births in 1000s (LB+SB) per year	193	Unicef, 2013				
Infant mortality rate: infant deaths / 1000 LB / year	46.3	Unicef, 2013				
Under-5 mortality rate: U5 deaths / 1000 LB / year	67.8	Unicef, 2013				
Percentage births in women >35 years						
Life expectancy at birth (yrs)	61.60	Unicef, 2013				
% of marriages consanguineous						

	Estimate	Source, Year	Your	Source,	Chosen	Source,
Maternal health			estimate	Year	estimate	Year
Prenatal visits – at least 1 visit (%)	70.3	Unicef, 2013				
Prenatal visits – at least 4 visits (%)	40.9	Unicef, 2013				
Births attended by skilled health personnel (%)	28.3	Unicef, 2013				
Contraception prevalence rate (%)	8.0	Unicef, 2013				
Unmet need for family planning (%)	27	WHO, 2002				
Total fertility rate	4.37	Unicef, 2013				
% home births						
% births at health care services	26.40	Unicef, 2013				
	Estimate	Source, Year	Your	Source,	Chosen	Source,
Newborn health			estimate	Year	estimate	Year
Number of neonatal examinations by SBA / trained staff						
% neonatal examinations by SBA/ trained staff						

Socio-economic indicators	Estimate	Source, Year		Chosen estimate	Source, Year
Gross national income per capita (PPP int. \$)	580	Unicef, 2013			
% population living on < US\$1 per day		Unicef, 2013			
Birth registration coverage (%)					
Death registration coverage (%)					

LB = live births

PPP = purchasing power parity SBA = skilled birth attendant

**PHG** Foundation

Eritrea Shared Data Health Services Data

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Health Services information from that Calculator into here. The information should be the same.

This section provides health-service-related information for your country.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Health Expenditure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Per capita total expenditure on health (PPP int. \$)	17	WHO 2011				
Total expenditure on health as percentage of GDP	2.6	WHO 2011				
Per capita government expenditure on health (PPP int. \$)	8.3	WHO 2011				
External resources for health as percentage of total expenditure on health	69.1	WHO 2011				
General government expenditure on health as percentage of total expenditure on health	48.8	WHO 2011				
Out-of-pocket expenditure as percentage of private expenditure on health	100	WHO 2011				
Private expenditure on health as percentage of total expenditure on health	51.2	WHO 2011				
General government expenditure on health as percentage of total government expenditure	3.6	WHO 2011				

Health Workforce	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Number of nursing and midwifery personnel	2505	WHO, 2004				
Nursing and midwifery personnel density (per 10,000 population)	5.8	WHO, 2004				
Number of physicians	215	WHO, 2004				
Physician density (per 10,000 population)	0.5	WHO, 2004				
Number of obstetricians						
Number of paediatricians						
Number of paediatric surgeons						
Number of paediatric cardiac surgeons						
Number of paediatric neurosurgeons						
Number of clinical geneticists						
Number of genetic counsellors						
Number of community health workers						
Number of skilled birth attendants (SBA)						
Density of SBA						
Number of lab staff providing cytogenetic testing						

PHG Foundation
----------------

Number of lab staff providing molecular genetics			
Number of lab staff providing biochemical tests for genetics			
Number of skilled health attendants			

		Source,	Your	Source,	Chosen	Source,
Infrastructure	Estimate	Year	estimate	Year	estimate	Year
Number of maternity units						
Number of services providing specialised care for people with CD						
Number of family planning services						
Number of preconception services						
Number of services providing prenatal care						
Number of services providing newborn care						
Number of facilities providing genetic services						
Number of laboratories providing cytogenetics						
Number of laboratories providing molecular genetics						
Number of laboratories providing biochemical tests for genetics						
Number of facillities for safe terminations of pregnancies for fetal defects						

PPP = purchasing power parity

GDP = gross domestic product SBA = skilled birth attendant

CD = congenital disorders

Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 1.1: Country epidemiology

Epidemiological indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of estimate						
Prevalence at birth and by age-group (/10	)0)					
Live birth prevalence (LB)			0.10			
Stillbirth prevalence (SB)			0.00			
Total birth prevalence (LB+SB)			0.10			
All age groups						
<1 year olds						
1-4 year olds						
5-14 year olds						
15-44 year olds						
45+ year olds						
Number of cases by age group						
Annual live births			19			
All age groups						
<1 year olds						
1-4 year olds						
5-14 year olds						
15-44 year olds						
45+ year olds						
No. of cases by level of impairment					· ·	
No or minor disability						
Moderate disability						
Severe disability*						
Mortality and morbidity					·	
Mean life expectancy (yrs)			7			
No. deaths < 1yr			13			
No. deaths 1-4 yrs			4			
No. deaths < 5 yrs			18			
Infant mortality / 1000 LB			0.07			
Under-5 mortality / 1000 LB			0.10			
Years of life lost						

### Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 1.2: International comparison

Comparison Your chosen **Epidemiological indicator** estimates Country Region World Prevalence at birth and by age-group (/1000 people) (Sub-Saharan Africa, East) Live birth prevalence (LB) 0.10 0.93 1.29 0.00 Stillbirth prevalence (SB) 0.00 0.00 Total birth prevalence (LB+SB) 0.10 1.29 0.93 All age groups <1 year olds 1-4 year olds 5-14 year olds 15-44 year olds 45+ year olds Number of cases by age-group 19 Annual live births 11733 173444 All age groups <1 year olds 1-4 year olds 5-14 year olds 15-44 year olds 45+ year olds No. cases by level of impairment No or minor disability Moderate disability Severe disability Mortality and morbidity Mean life expectancy (yrs) 7 3.80 32.36 13 8354 110838 No. deaths < 1yr 4 2785 36940 No. deaths 1-4 yrs No. deaths < 5 yrs 18 11139 147778 0.71 0.64 Infant mortality / 1000 LB 0.07 Under-5 mortality / 1000 LB 0.10 0.95 0.85 Years of life lost

Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 2.1: Data on affected pregnancies: Research studies

Study author, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies listed above (or in section SCD-E2.1 of the Tool), enter the best estimates for the prevalence of affected births and terminations in the country, and a range of values to reflect uncertainty or within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	LB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			
Estimates for the total country/territory	Number of affected stillbirths	SB prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

## Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 2.2: Data on affected pregnancies: Surveillance

Based on surveillance data, enter the best estimates for the prevalence of the condition in live births and still births in the country. Give a range of values to reflect uncertainty and within-country variation, and use comments for information on data quality, uncertainty and representativeness.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the total country/territory	Number of affected live births	Birth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

	Number of affected stillbirths	Stillbirth prevalence / 1000 TB	Comments
Best estimate			
Lower estimate			
Higher estimate			

# Glucose-6-phosphate dehydrogenase deficiency

G6PDD Epidemiology 2.3: Data on affected pregnancies: Other sources

	Source 1:	Source 2:	Notes
Enter year and source of data – use last year with information available.			
Basic Numbers			
Number of affected live births / year, from data source			]
Total number of live births / year, from data source			
Number of affected still births / year, from data source			]
Total number of stillbirths / year, from data source			]
Total number of affected births / year (live and still)	(	) 0	
Total number of births / year, from data source	(	) 0	
Total number of women aged 15-44			]
Live birth prevalence: recorded and estimated			]
Recorded live birth prevalence (affected recorded live births / 1000 total births)	#DIV/0	! #DIV/0!	
Estimated completeness of recording: what proportion of true affected live births in your data source were recorded?	•		Range: 0 to 1
Estimated coverage of recorded live births (number of recorded live births / total live births in country or territory)			Range: 0 to 1
Estimated live birth prevalence (recorded prevalence / completeness)	#DIV/0	! #DIV/0!	
Estimated true number of affected live births in data source (number of recorded affected live births / completeness)	#DIV/0	! #DIV/0!	
Estimated number of affected live births in total population (number of affected live births from data source / (coverage x completeness))	#DIV/0	! #DIV/0!	
Stillbirth prevalence: recorded and estimated			1
Recorded stillbirth prevalence (affected recorded still births / 1000 recorded total births)	#DIV/0	! #DIV/0!	1
Estimated completeness of recording: what proportion of true affected stillbirths in your data source were recorded?			Range: 0 to 1
Estimated coverage of recorded stillbirths (number of recorded still births / total still births in country or territory)			Range: 0 to 1
Estimated stillbirth prevalence (recorded prevalence / completeness)	#DIV/0	! #DIV/0!	
Estimated true number of affected stillbirths in data source (number of recorded affected still births / completeness)	/ #DIV/0	! #DIV/0!	
Estimated number of affected still births in total population (number of affected still births from data source / (coverage x completeness))	#DIV/0	! #DIV/0!	

Based on the sources above, enter the best prevalence estimates for your population, and a range of values to reflect uncertainty of estimates and within country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

Estimates for the whole country/territory	Number of affected live births	LB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		
Estimates for the whole country/territory	Number of affected stillbirths	SB prevalence / 1000 TB
Best estimate		
Lower estimate		
Higher estimate		

## Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 2.4: Summary of affected pregnancies

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Number of annual affected live births			19			
Annual birth prevalence / 1000 TB			0.10			
Number of annual affected still births			0			
Stillbirth prevalence / 1000 TB/year			0.00			

If there are specific sub-types of condition, you can repeat this exercise below. However, you should consider (a) whether subtypes would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

# Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 2.5: Sub-population variation in affected pregnancies

If the birth prevalence rates vary by population sub-group (e.g. geographically or by another factor), indicate any population groups with different prevalence estimates from the whole population and describe reasons for variation. If a group is substantially different from the general population, you may wish to conduct a needs assessment for that group alone.

Population sub- group	Number of affected live births	LB prevalence / 1000 TB	Reason for variation

Population sub- group	Number of affected stillbirths	SB prevalence / 1000 TB	Reason for variation

# Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 3.1: Mortality data: Research studies

Source, year, site	Sample size	Study quality and representativeness	Main findings

Based	on the	studies	above,	enter the	e best	estimates	s for the	specific	mortality by	age-group	e.g.
infant,	under-	5s, etc.,	as app	ropriate,	and a	range of	values t	o reflect	uncertainty	of estimates	and
within-	country	variatic	on.								

If studies are no	ot representative	of the nationa	I population	you may	need to	o weight y	our data	(see
the Guide for ex	planation on wei	ghting and he	Ip with the c	alculation	າຣ).			

Mortality estimates	Number of deaths	Ratio (deaths / 1000 LB)	Comments
Neonatal group (<28 days)			
Best estimate			
Lower estimate			
Higher estimate			
Infant group (<1 year)			
Best estimate			
Lower estimate			
Higher estimate			
Under-5 group (<5 years)			
Best estimate			
Lower estimate			
Higher estimate			
Other age group:			
Best estimate			
Lower estimate			
Higher estimate			

LB = live births

# Glucose-6-phosphate dehydrogenase deficiency

G6PDD Epidemiology 3.2: Mortality data: Vital registration data

Fill in the blank cells based on your vital registration data.		
Enter year and source of data		
Registered data		
Total registered live births		
Registered condition-specific neonatal deaths (first 28 days of life)		
Registered condition-specific infant deaths (first year of life)		
Registered condition-specific under-5 deaths (first 5 years of life)		
Registered condition-specific neonatal mortality ratio	#DIV/0!	
(condition-specific neonatal deaths / 1000 live births in the same year)		
Registered condition-specific infant mortality (condition-specific infant deaths / 1000 live births in the same year)	#DIV/0!	
Registered condition-specific under-5 mortality (condition-specific under-5 deaths / 1000 live births in the same	#DIV/0!	
year)		

Adjustment for under-ascertainment of cause of death and sub-registration of deaths: Enter estimates in the highlighted cells. It is not always possible to adjust the estimates, in which case you may give the value '1', accepting that the estimates in these cases will usually be biased towards low values. (Or you may move to the next section.) It is assumed that under-ascertainment is stable across age-groups; if ascertainment varies by age-group, you could use separate estimates for each age group.

Estimated completeness of recording: what proportion of deaths in affected persons were registered as such?	Range: 0 to 1
Population coverage: what proportion of the total country/territory population is covered by the vital registration	Range: 0 to 1
Death ascertainment (population coverage x completeness)	0
Estimated values for the total country/ territory population	
Estimated number of live births in total population	#DIV/0!
Estimated number of neonatal deaths in total population (number of deaths registered in neonatal period / ascertainment)	#DIV/0!
Estimated number of infant deaths in total population (number of deaths registered in first year of life / ascertainment)	#DIV/0!
Estimated number of under-5 deaths in total population (number of deaths registered in under-5s / ascertainment)	#DIV/0!
Estimated neonatal mortality ratio (estimated neonatal deaths / 1000 live births)	#DIV/0!
Estimated infant mortality ratio (estimated infant deaths / 1000 live births)	#DIV/0!
Estimated under-5 mortality ratio (estimated under-5 deaths / 1000 live births)	#DIV/0!

## Eritrea Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 3.3: Mortality data: Other sources

Source, year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Neonatal mortal	ity	Infant mortality		Under-5 mortality	
Estimates for the total country/territory	Value	Ratio/1000 LB	Value	Ratio/1000 LB	Value	Ratio/1000 LB
Best estimate						
Lower estimate						
Higher estimate						

## Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 3.4: Summary mortality estimates

Indicator	Your estimates	Range	PHGDB minimum estimates	Chosen estimates	Range	Source
Year of data collection						
Number of annual deaths in affected persons						
Number of annual live births (in 1000s)			183			
Number of annual affected neonatal deaths			7			
Number of affected neonatal deaths / 1000 LB			0.04			
Number of annual affected infant deaths			13			
Number of affected infant deaths / 1000 LB			0.07			
Number of annual affected under-5 deaths	1		18			
Number of affected under-5 deaths / 1000 LB	ĺ		0.10			
Mean life expectancy at birth in affected people	1		7			
Other indicators (e.g. survival following surgical procedure, etc)						

# Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 3.5: Sub-population variation in mortality

Age group: neonatal Population sub-group	Cause-specific, group-specific neonatal mortality ratio / 1000 LB	Reason for variation

Age group: infant Population sub-group	Cause-specific, group-specific infant mortality ratio / 1000 LB	Reason for variation

		Cause-specific, group-specific	Reason for variation
Population sub-group	affected persons	under-5 mortality ratio / 1000 LB	

Age group:			Reason for variation
Population sub-group	affected persons	mortality ratio / 1000 population	

# Glucose-6-phosphate dehydrogenase deficiency

G6PDD Epidemiology 4.1: Population prevalence: Research studies

Study, year, site	Sample size	Study quality and representativeness	Main findings

Based on the studies above, enter the best estimates for population prevalence, and a range of values to reflect uncertainty of estimates and within-country variation.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

# Glucose-6-phosphate dehydrogenase deficiency

G6PDD Epidemiology 4.2: Population prevalence: Other sources

Source, year, site	Sample size	Data quality and representativeness	Main findings

Based on data from the sources above, enter estimates for the disease-specific deaths and mortality rates in your population.

If studies are not representative of the national population you may need to weight your data (see the Guide for explanation on weighting and help with the calculations).

	Prevalence / 1000 persons	Range	Comments
Best estimate			
Lower estimate			
Higher estimate			

## Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 4.3: Summary of population prevalence

Source of estimates	Estimated total population number of affected persons	Range	Estimated total population prevalence / 1000 persons	Range
1				
2				
3				
4				
5				
PHGDB				
Chosen estimates				

### Glucose-6-phosphate dehydrogenase deficiency G6PDD Epidemiology 4.4: Sub-population prevalence variation

Population sub-group	Number of affected people	· ·	Population prevalence per 1000 people	Reason for variation
			#DIV/0!	

If there are specific sub-types of condition, you can repeat this exercise (copy table and paste below). However, you should consider (a) whether sub-types would have different implications for advocacy, and (b) whether a sub-type might require a full, specific needs assessment.

Formula in column D: Number of affected people/ (Total number of people in population subgroup/1000)

Glucose-6-phosphate dehydrogenase deficiency G6PDD Intervention 1:Effects of NBS and treatment on G6PDD

## Screened

Baseline birth prevalence of G6PDD, per 1000 TB*		
Variables		
Coverage of newborn screening	0	Range: 0 to 1
Proportion of positive-screened patients receiving treatment		Range: 0 to 1
Effectiveness of treatment in screened patients		Range: 0 to 1
Results		
Proportional reduction of unmanaged cases of G6PDD through NBS and treatment <sup>1</sup>	0	
Prevalence of unmanaged G6PDD due to newborn screening and treatment, per 1000 total births <sup>2</sup>	0	
Unscreened		
Birth prevalence of unscreened G6PDD, per 1000	0	
Variables		
Estimated coverage of clinical diagnosis in unscreened patients		Range: 0 to 1
Proportion of unscreened patients diagnosed clinically receiving treatment		Range: 0 to 1
Effectiveness of treatment in unscreened patients		Range: 0 to 1
Results		
Proportional reduction of unscreened unmanaged cases of G6PDD through clinical diagnosis and treatment <sup>3</sup>	0	
Prevalence of unscreened unmanaged G6PDD following clinical diagnosis, per 1000 total births⁴	0	

# Total

Prevalence of unmanaged G6PDD following treatment in both screen-detected and clinically-detected patients, per 1000 total births<sup>5</sup>

TB = total births (live births + still births)

G6PDD = Glucose-6-Phosphate Dehydrogenase Deficiency

\* If you don't have data on birth prevalence but do have data on screening, you can estimate birth prevalence by combining the proportion screened positive with the number of total births. (This assumes that screening is randomly distributed in the population)

0

<sup>1</sup>Coverage of newborn screening x Proportion of positive screened patients receiving treatment x Effectiveness of treatment in screened patients

<sup>2</sup>Baseline birth prevalence -(proportional reduction of unmanaged cases of G6PDD through NBS and treatment x Baseline birth prevalence)

<sup>3</sup>Coverage of clinical diagnosis in unscreened patients x Proportion of clinically diagnosed patients receiving treatment x Effectiveness of treatment in unscreened patients

<sup>4</sup>Birth prevalence of unscreened G6PDD – (Proportional reduction of unscreened unmanaged cases through clinical diagnosis x Birth prevalence of unscreened G6PDD)

## Eritrea Glucose-6-phosphate dehydrogenase deficiency G6PDD Needs Assessment Calculator 1: Quantitative baseline

# Table SCD-NA1a Burden of Glucose-6-phosphate dehydrogenase deficiency in pregnancy, at birth and at population level

		Chosen estimates		
Indicator	Number (n)		Range of prevalence (/1000 TB)	
Annual affected live births (LB)	0	0	0	Drawn from sheet E2.4
Annual affected stillbirths (SB)	0	0	0	Drawn from sheet E2.4
Annual affected births (LB+SB)	0	0		Drawn from sheet E2.4
Annual affected persons (all age groups)	0	0	0	Drawn from sheet E1.1

# Table SCD-NA1b Glucose-6-phosphate dehydrogenase deficiency mortality indicators

	Chosen estimates Notes			
Indicator	Number (n)		Range of prevalence (/1000 TB)	
Annual overall mortality	0			Drawn from sheet E3.4
Annual neonatal mortality	0	0	0	Drawn from sheet E3.4
Annual infant mortality	0	0	0	Drawn from sheet E3.4
Annual under-5 mortality	0	0	0	Drawn from sheet E3.4
Mean life expectancy at birth among affected people	0		0	Drawn from sheet E3.4

Glucose-6-phosphate dehydrogenase deficiency G6PDD Needs Assessment Calculator 3: Quantitative assessment of interventions

Table G6PDD-NA3a	Estimated prevalence in the absence of interventions for Glucose-6-phosphate dehydrogenase deficiency		
Indicator	Number (n)	Prevalence (n/1000)	
Potential live births			
Potential still births			

Table G6PDD-NA3b	Current situation in relation to interventions before birth			
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 LB	
Effect of family planning, education				
Effect of population carrier screening				
Effect of preconception screening				
Effect of prenatal screening				
Overall effect				

Table G6PDD-NA3c	Target situation in relation to interventions before birth				
Intervention	Coverage (%)	Cases averted (n)	Cases averted/1000 LB		
Effect of family planning, education					
Effect of population carrier screening					
Effect of preconception screening					
Effect of prenatal screening					
Overall effect					

Table G6PDD-NA3d	Current situation in relation to interventions after birth				
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 LB		
Effect of newborn screening					
Effect of newborn diagnosis					
Treatment of newborn					
Haemolysis prevention					
Haemolysis treatment post neonatal					
Effect of social care and support					
Overall effect					

Table G6PDD-NA3e	Target situation in relation to interventions after birth				
Intervention	Coverage (%)	Cases managed (n)	Cases managed/1000 LB		
Effect of newborn screening					
Effect of newborn diagnosis					
Treatment of newborn					
Haemolysis prevention					
Haemolysis treatment post neonatal					
Effect of social care and support					
Overall effect					

Table G6PDD-NA3f	Current and desired	Current and desired outcomes Current situation		
	Current situation			Target situation
Indicator	Annual number (n)	Incidence (n/1000)	Annual number (n)	Incidence (n/1000)
Estimated affected pregnancies			· ·	· · ·
Live births (LB)		0	0	
Still births (SB)		0	0	
All births (LB+SB)		0	0	
Estimated population prevalence	)			
All age groups				
Estimated mortality			· · ·	· · · ·
Neonatal deaths		0	0	
Infant deaths		0	0	
Under-5 deaths		0	0	